Payment overview · 2025
General Payments
$258.75
15 reported records · 8 companies
Healthcare provider profile · identity verified
Marc D Radabaugh, MD
Allopathic & Osteopathic Physicians|Family Medicine · RICHMOND HEIGHTS, MO · NPI 1104358670
Verified facts
What the public records show
CMS Open Payments records show Marc D Radabaugh, MD received $258.75 in general payments during 2025 across 15 reported records.
Lilly USA, LLC accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.95 | 37.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.83 | 17.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.37 | 12.9% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $18.64 | 7.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.64 | 7.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.56 | 6.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.18 | 5.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.58 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $258.75 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.36 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.59 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.37 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 20 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 105 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 967 | 274 |
| Amlodipine Besylate | Amlodipine Besylate | 659 | 178 |
| Lisinopril | Lisinopril | 423 | 115 |
| Losartan Potassium | Losartan Potassium | 395 | 112 |
| Hydrochlorothiazide | Hydrochlorothiazide | 337 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 322 | 83 |
| Metformin Hcl | Metformin Hcl | 284 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 62 |
| Furosemide | Furosemide | 183 | 64 |
| Gabapentin | Gabapentin | 176 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 61 |
| Chlorthalidone | Chlorthalidone | 155 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 38 |
| Tramadol Hcl | Tramadol Hcl | 141 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 42 |
| Omeprazole | Omeprazole | 131 | 45 |
| Allopurinol | Allopurinol | 125 | 38 |
| Carvedilol | Carvedilol | 122 | 39 |
| Eliquis | Apixaban | 105 | 31 |
| Famotidine | Famotidine | 103 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 31 |
| Alendronate Sodium | Alendronate Sodium | 94 | 29 |
| Alprazolam | Alprazolam | 90 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 27 |
| Ozempic | Semaglutide | 71 | 14 |
| Simvastatin | Simvastatin | 68 | 21 |
| Meloxicam | Meloxicam | 65 | 15 |
| Methylprednisolone | Methylprednisolone | 65 | 53 |
| Montelukast Sodium | Montelukast Sodium | 63 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 12 |
| Potassium Chloride | Potassium Chloride | 46 | 17 |
| Sertraline Hcl | Sertraline Hcl | 46 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Prednisone | Prednisone | 43 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 16 |
| Glipizide | Glipizide | 42 | 12 |
| Atenolol | Atenolol | 41 | 13 |
| Azelastine Hcl | Azelastine Hcl | 41 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 12 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 18 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Benzonatate | Benzonatate | 32 | 20 |
| Spironolactone | Spironolactone | 32 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Clotrimazole | Clotrimazole | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 26 | 11 |
| Torsemide | Torsemide | 26 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 19 |
| Baclofen | Baclofen | 20 | suppressed |
| Galantamine Er | Galantamine Hbr | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $258.75 · 15 records | Lilly USA, LLC | AREXVY, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, Prolastin-C Liquid, REPATHA, SHINGRIX, VOQUEZNA, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error